10 results on '"Girard, Philippe"'
Search Results
2. International Delphi survey of the ESTS/AATS/ISTH task force on venous thromboembolism prophylaxis in thoracic surgery: the role of extended post-discharge prophylaxis
- Author
-
Agzarian, John, primary, Litle, Virginia, primary, Linkins, Lori-Ann, primary, Brunelli, Alessandro, primary, Schneider, Laura, primary, Kestenholz, Peter, primary, Li, Hui, primary, Rocco, Gaetano, primary, Girard, Philippe, primary, Nakajima, Jun, primary, Samama, Charles Marc, primary, Scarci, Marco, primary, Anraku, Masaki, primary, Falcoz, Pierre-Emmanuel, primary, Bertolaccini, Luca, primary, Lin, Jules, primary, Murthy, Sudish, primary, Hofstetter, Wayne, primary, Okumura, Meinoshin, primary, Solli, Piergiorgio, primary, Minervini, Fabrizio, primary, Kirk, Alan, primary, Douketis, James, primary, and Shargall, Yaron, primary
- Published
- 2019
- Full Text
- View/download PDF
3. Venous thromboembolism prophylaxis in thoracic surgery patients: an international survey
- Author
-
Shargall, Yaron, primary, Brunelli, Alessandro, additional, Murthy, Sudish, additional, Schneider, Laura, additional, Minervini, Fabrizio, additional, Bertolaccini, Luca, additional, Agzarian, John, additional, Linkins, Lori-Ann, additional, Kestenholz, Peter, additional, Li, Hui, additional, Rocco, Gaetano, additional, Girard, Philippe, additional, Venuta, Federico, additional, Samama, Marc, additional, Scarci, Marco, additional, Anraku, Masaki, additional, Falcoz, Pierre-Emmanuel, additional, Kirk, Alan, additional, Solli, Piergiorgio, additional, Hofstetter, Wayne, additional, Okumura, Meinoshin, additional, Douketis, James, additional, and Litle, Virginia, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Second pulmonary resection for a second primary lung cancer: analysis of morbidity and survival.
- Author
-
Abid, Walid, Seguin-Givelet, Agathe, Brian, Emmanuel, Grigoroiu, Madalina, Girard, Philippe, Girard, Nicolas, and Gossot, Dominique
- Subjects
LUNG cancer ,SURVIVAL rate ,OVERALL survival ,NON-small-cell lung carcinoma ,SURVIVAL analysis (Biometry) - Abstract
Open in new tab Download slide Open in new tab Download slide OBJECTIVES Evaluating morbidity and survival of patients operated on for a second primary non-small-cell lung cancer (NSCLC). METHODS Retrospective collection of data from patients operated on for a second NSCLC between 2009 and 2018. RESULTS Fifty-two patients met the inclusion criteria. At the time of second pulmonary resection, the median time between the 2 surgeries was 25 months (5–44.5 months). Patients' median age was 65 years (61–68 years). Median tumour size was 16 mm (10–22 mm). Thoracoscopy was used in 75% of cases. The resection was a pneumonectomy (n = 1), bilobectomy (n = 1), lobectomy (n = 15), segmentectomy (n = 32) or wedge resection (n = 3). The length of stay was 7 days (5–9 days). Mortality was null and morbidity was 36.5%, mainly from grade I–II complications according to the Clavien–Dindo classification. The median follow-up was 28 months (13–50 months). The median overall survival was 67 months (95% confidence interval 60.8–73.1 months). Survival at 5 years and specific survival were 71.1% and 67.7%, respectively. CONCLUSIONS A second surgical resection of either synchronous or metachronous NSCLC has a morbidity that is not superior to the morbidity of the first operation. The new tumour is usually diagnosed at an early stage. An anatomical sublobar resection is most likely the best compromise. It might also be considered for the first operation when there is a suspicious synchronous lesion that may require surgery at a later stage. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. International Delphi survey of the ESTS/AATS/ISTH task force on venous thromboembolism prophylaxis in thoracic surgery: the role of extended post-discharge prophylaxis.
- Author
-
Agzarian, John, Litle, Virginia, Linkins, Lori-Ann, Brunelli, Alessandro, Schneider, Laura, Kestenholz, Peter, Li, Hui, Rocco, Gaetano, Girard, Philippe, Nakajima, Jun, Samama, Charles Marc, Scarci, Marco, Anraku, Masaki, Falcoz, Pierre-Emmanuel, Bertolaccini, Luca, Lin, Jules, Murthy, Sudish, Hofstetter, Wayne, Okumura, Meinoshin, and Solli, Piergiorgio
- Subjects
TASK forces ,PREVENTIVE medicine ,VENOUS thrombosis ,THORACIC surgery - Abstract
Open in new tab Download slide Open in new tab Download slide OBJECTIVES Venous thromboembolic events can be successfully prevented with chemical and/or mechanical prophylaxis measures, but evidence-based guidelines in thoracic surgery are limited, particularly regarding extended post-discharge prophylaxis. This study attempts to gather an international consensus on best practices to inform the development of such guidelines. METHODS A series of 3 surveys was distributed to the ESTS/AATS/ISTH (European Society of Thoracic Surgeons, American Association of Thoracic Surgeons, International Society for Thrombosis and Haemostasis) venous thromboembolic events prophylaxis working group starting January 2017. This iterative Delphi consensus process sought to gather a consensus on (i) risk factors; (ii) preferred agents; (iii) duration; and (iv) perceived barriers to an extended thromboprophylaxis approach. Participant responses were expressed on a 10-point scale, and the results were summarized and circulated to all respondents in subsequent rounds. A coefficient of variance of ≤0.3 was identified pre hoc to identify agreement. RESULTS A total of 21 Working Group members completed the surveys, composed of 19% non-surgeon thrombosis experts, and 48% from North America. Respondents largely saw agreement regarding risk factors that indicate a need for extended thromboprophylaxis. The group agreed that low-molecular-weight heparin is a suitable agent for use post-discharge, but there was a wide variety in response regarding agents, duration and barriers to extended prophylaxis, where no consensus was observed across the three rounds. CONCLUSIONS There is strong agreement around indications for extended venous thromboembolic events thromboprophylaxis after thoracic surgery, but there is little consensus regarding the agents and duration to be employed. Further research is required to better inform guideline development. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Venous thromboembolism prophylaxis in thoracic surgery patients: an international survey.
- Author
-
Shargall, Yaron, Brunelli, Alessandro, Murthy, Sudish, Schneider, Laura, Minervini, Fabrizio, Bertolaccini, Luca, Agzarian, John, Linkins, Lori-Ann, Kestenholz, Peter, Li, Hui, Rocco, Gaetano, Girard, Philippe, Venuta, Federico, Samama, Marc, Scarci, Marco, Anraku, Masaki, Falcoz, Pierre-Emmanuel, Kirk, Alan, Solli, Piergiorgio, and Hofstetter, Wayne
- Subjects
THORACIC surgery ,PATIENT surveys ,DENTAL prophylaxis ,PREVENTIVE medicine ,THORACIC surgeons ,CARDIOVASCULAR surgery - Abstract
Open in new tab Download slide Open in new tab Download slide OBJECTIVES Venous thromboembolic events (VTE) after thoracic surgery (TS) can be prevented with mechanical and chemical prophylaxis. Unlike other surgical specialties, TS lacks evidence-based guidelines. In the process of developing these guidelines, an understanding of the current prophylaxis methods practiced internationally is necessary and is described in this article. METHODS A 26-item survey was distributed to members of the European Society of Thoracic Surgeons (ESTS), American Association of Thoracic Surgery (AATS), Japanese Association for Chest Surgery (JACS) and Chinese Society for Thoracic and Cardiovascular Surgery (CSTCS) electronically or in person. Participants were asked to report their current prophylaxis selection, timing of initiation and duration of prophylaxis, perceived risk factors and the presence and adherence to institutional VTE guidelines for patients undergoing TS for malignancies. RESULTS In total, 1613 surgeons anonymously completed the survey with an overall 36% response rate. Respondents were senior surgeons working in large academic hospitals (≥70%, respectively). More than 83.5% of ESTS, AATS and JACS respondents report formal TS thromboprophylaxis protocols in their institutions, but 53% of CSTCS members report not having such a protocol. The regions varied in the approaches utilized for VTE prophylaxis, the timing of initiation perioperatively and the use and type of extended prophylaxis. Respondents reported that multiple risk factors and sources of information impact their VTE prophylaxis decision-making processes, and these factors vastly diverge regionally. CONCLUSIONS There is little agreement internationally on the optimal approach to thromboprophylaxis in the TS population, and guidelines will be helpful and vastly welcomed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Oncological results of full thoracoscopic major pulmonary resections for clinical Stage I non-small-cell lung cancer
- Author
-
Lutz, Jon A, primary, Seguin-Givelet, Agathe, additional, Grigoroiu, Madalina, additional, Brian, Emmanuel, additional, Girard, Philippe, additional, and Gossot, Dominique, additional
- Published
- 2018
- Full Text
- View/download PDF
8. Oncological results of full thoracoscopic major pulmonary resections for clinical Stage I non-small-cell lung cancer.
- Author
-
Lutz, Jon A, Seguin-Givelet, Agathe, Grigoroiu, Madalina, Brian, Emmanuel, Girard, Philippe, and Gossot, Dominique
- Abstract
View large Download slide View large Download slide OBJECTIVES The full thoracoscopic approach to major pulmonary resections is considered challenging and controversial as it might compromise oncological outcomes. The aim of this work was to analyse the results of a full thoracoscopic technique in terms of nodal upstaging and survival in patients with non-small-cell lung carcinoma (NSCLC). METHODS All patients who underwent a full thoracoscopic major pulmonary resection for NSCLC between 2007 and August 2016 were analysed from an 'intent-to-treat' prospective database. Overall survival and disease-free survival were estimated using the Kaplan–Meier curves and comparisons in survival using the log-rank test. RESULTS A total of 648 patients met the inclusion criteria, of whom 621 patients had clinical Stage I and 27 had higher stages (16 oligometastatic patients were excluded from the analysis, 11 cT3 or cT4). The mean follow-up was 34.5 months. There were 40 conversions to thoracotomy (6.3%). Thirty-day or in-hospital mortality was 0.95%. Complications occurred in 29.3% of patients. On pathological examination, 22.5% of clinical Stage I patients were upstaged. Nodal upstaging to N1 or N2 was observed in 15.8% of clinical Stage I patients. Five-year overall survival of the whole cohort was 75% and was significantly different between clinical Stages IA (76%) and IB (70.9%). For tumours <2 cm, no significant difference in overall survival was found for the segmentectomy group compared to the lobectomy group: 74% versus 78.9% (P = 0.634). CONCLUSIONS Long-term survival is not compromised by a full thoracoscopic approach. Our results compared favourably with those of video-assisted techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Thoracoscopic resection of bulky intrathoracic benign lesions
- Author
-
Gossot, Dominique, primary, Izquierdo, Ricard Ramos, additional, Girard, Philippe, additional, Stern, Jean-Baptiste, additional, and Magdeleinat, Pierre, additional
- Published
- 2007
- Full Text
- View/download PDF
10. Mediastinal lymph node dissection in early-stage non-small cell lung cancer: totally thoracoscopic vs thoracotomy†.
- Author
-
Ramos, Ricard, Girard, Philippe, Masuet, Cristina, Validire, Pierre, and Gossot, Dominique
- Subjects
- *
LUNG cancer treatment , *LYMPH node surgery , *DISSECTION , *CHEST endoscopic surgery , *THORACOSCOPY , *COMPARATIVE studies - Abstract
OBJECTIVES Although major pulmonary resections for early-stage non-small cell lung cancer (NSCLC) are more and more frequently performed through thoracoscopy, the adequacy of lymphadenectomy achieved via this approach is still questioned. The aim of this study was to evaluate the results of lymph node dissection (LND) during totally thoracoscopic (TT) major pulmonary resections. METHODS Clinical and pathological data of consecutive patients who underwent lobectomy or segmentectomy for clinical-N0 NSCLC between 1 January 2007 and 31 December 2009 were reviewed. The main evaluation criterion was the number of mediastinal lymph nodes (LNs) and mediastinal stations dissected through a TT approach when compared with the classical posterolateral thoracotomy (PLT) approach. RESULTS A total of 296 major pulmonary resections (278 lobectomies and 18 anatomic segmentectomies) for clinical stages I–II NSCLC were performed, 96 via a TT approach and 200 through PLT. Patients' clinical characteristics were similar in both groups. The overall—i.e mediastinal and lobar—number of dissected mediastinal LNs and of dissected mediastinal stations were similar in both groups (TT: mean ± SD = 17.7 ± 8.2; PLT: 18.2 ± 9.3(P < 0.937) and 3.2 ± 0.9 vs 3.4 ± 0.9, respectively). The overall numbers of stations (TT: mean ± SD 5.1 ± 1.1; PLT: 4.5 ± 1.2) and LNs (TT: 22.6 ± 9.4, PLT: 25.4 ± 10.8) were slightly but significantly different between the two groups (P < 0.001 and P = 0.033, respectively); there was no difference in terms of post-operative complications, although patients from the TT group had significantly fewer days with the chest tube (mean ± SD = 4.0 ± 1.8 vs 5.7 ± 3.9, P < 0.001) and shorter length of stay (7.0 ± 2.5 days vs 10.3 ± 7.4, P < 0.001). CONCLUSIONS For patients undergoing thoracoscopic lobectomy or segmentectomy for clinical early-stage NSCLC, the quality of mediastinal LND is equivalent to that performed by thoracotomy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.